Results 11 to 20 of about 51,359 (249)
Archives of Pharmaceutical Sciences Ain Shams University, 2021 Transcription factors (TFs) as SRY-Box transcription factor 11 (SOX11) and B-cell lymphoma/leukemia 11A (BCL11A) role in breast cancer (BC) as well as their effect on epithelial cadherin (E-cadherin) membrane protein which is a metastasis suppressor is a
Salma Salama +3 more
doaj +1 more source
OncoImmunology, 2020 Triple-negative breast cancer is the most aggressive subtype of breast cancer and is difficult to treat. Breast cancer is considered to be poorly immunogenic and hence is less responsive to immunotherapies.
Shyambabu Chaurasiya +10 more
doaj +1 more source
Aging, 2015 Among all breast cancer molecular subtypes, triple-negative breast cancer (TNBC) presents the poorest prognosis due to the lack of effective therapeutic options. TNBC, characterized by tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or HER-2 genes, represents approximately 10%–20% of invasive breast cancers and has been ...
Nadia P, Castro, David S, Salomon
openaire +2 more sources
Chemotherapy with ceramide in TNBC
Oncoscience, 2015 Metastasis remains the major cause of cancer-related mortality, and currently there is a lack of therapies to eliminate this risk. Therefore, it is of crucial interest to better understand this multi-step cellular process and find the best markers to identify patients who will develop early and distant relapse.
Legembre, Patrick +2 more
openaire +3 more sources
Regulation of p53 and survivin by Curcuma longa extract to caspase-3 dependent apoptosis in triple negative breast cancer cells [PDF]
Medicinski Glasnik, 2022 Aim Triple negative breast cancer cells (TNBC) are the population of breast cancer cells that are responsible for cancer recurrence and apoptosis resistance.
Deryne Anggia Paramita +3 more
doaj +1 more source
SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus
Cancer Biology & Therapy, 2023 Aberrant activation of the mTOR pathway is a characteristic alteration in triple-negative breast cancer, but the mTOR pathway inhibitor everolimus is not effective for the triple-negative breast cancer (TNBC) patients.
Wenwen Geng +4 more
doaj +1 more source
Drug Delivery, 2018 Gambogic acid (GA) is a naturally derived potent anticancer agent with extremely poor biocompatibility. In the present study, a novel of redox/pH dual-responsive multifunctional magnetic complex micelle (sPEG/HA/CSO-SS-Hex/Fe3O4/GA), which consisted of a
Mang Mang Sang +10 more
doaj +1 more source
The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells [PDF]
Asian Pacific Journal of Cancer Prevention, 2021 The progress from Boron Neutron Capture Therapy (BNCT) development urged us to explore new targeted and selective boron carriers. Firstly, we reported the successful synthesis of CCB-2 which exerts a cytotoxic effect against triple negative breast cancer (TNBC) cells.
Jenie, Riris Istighfari +5 more
openaire +2 more sources
Clinical and Experimental Obstetrics & Gynecology, 2023 Background: The population of older women (≥70 years old) with triple-negative breast cancer (TNBC) is increasing, but there are few prognostic studies for these patients.
Chongwu He +7 more
doaj +1 more source
PD-L1 expression in triple-negative breast cancer: a cross-sectional study in a Polish population
Polish Journal of Pathology, 2021 Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast carcinomas and represents an aggressive variant with a high mortality rate. PD-L1 is a protein that plays a pivotal role in suppressing the adaptive immune system.
Łukasz Szylberg +8 more
doaj +1 more source